« Return to News | Awards & Advancement

Insmed appoints Hayden, Jr. as executive chairman

Thursday, May 17, 2012 10:45 AM

Insmed, a Monmouth Junction, N.J.-based biopharmaceutical company focused on inhalants, has appointed Donald J. Hayden, Jr. as executive chairman of the company's board of directors.

Hayden has served as chairman of Insmed’s board of directors since December 2010.  In his new role, Hayden will continue to work closely with Insmed’s president and CEO Timothy Whitten, and the management team, in executing on the development plan for the company's lead product, Arikace (liposomal amikacin for inhalation).  He will also focus more directly on strategic planning and corporate development.

Hayden joined Insmed following the 2010 merger with Transave, where he had served as executive chairman since 2006. Prior to that position, Hayden had a 25-year career with Bristol-Myers Squibb, where he served in key executive roles, including president of global pharmaceuticals, executive vice president and president of Americas, executive vice president of the health care group and several others. Currently, Hayden also serves as lead independent director of Amicus Therapeutics and director of Otsuka Pharmaceuticals. In addition, he serves in board roles for several privately-held companies, including executive chairman of Azelon Pharmaceuticals, chairman of Vitae Pharmaceuticals and Satori Pharmaceuticals and director of Nora Therapeutics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.